Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00226
|
|||||
| Drug Name |
Saxagliptin
|
|||||
| Synonyms |
(1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3; BMS 477118-11; BMS-477118; BMS-477118-11; Kombiglyze XR (TN); OPC-262; Onglyza; Onglyza (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Type 2 diabetes [ICD11: 5A11] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H25N3O2
|
|||||
| Canonical SMILES |
C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
|
|||||
| InChI |
InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1
|
|||||
| InChIKey |
QGJUIPDUBHWZPV-SGTAVMJGSA-N
|
|||||
| CAS Number |
CAS 361442-04-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 315.4 | Topological Polar Surface Area | 90.4 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
0.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103500900
, 104096574
, 104253199
, 121147387
, 121362351
, 123051077
, 124758670
, 124772084
, 126618190
, 126644889
, 136340362
, 137251549
, 139567127
, 144076400
, 144206461
, 152035966
, 160655903
, 160967860
, 162011574
, 162164961
, 16328544
, 16675586
, 175267813
, 175610961
, 178102934
, 184811995
, 223668663
, 223705237
, 224543974
, 225361148
, 226407286
, 23422497
, 246280642
, 251970941
, 252154978
, 252447400
, 42323525
, 46512075
, 57304394
, 75512904
, 92722527
, 96025679
, 99443245
|
|||||
| ChEBI ID |
CHEBI:71272
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [2] | |
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [3] | ||
| OATP4C1 | Transporter Info | Organic anion transporting polypeptide 4C1 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
| References | ||||||
| 1 | Linagliptin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010 Sep;49(9):573-88. | |||||
| 3 | Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. | |||||
| 4 | Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.